DURECT Corporation is an emerging specialty pharmaceutical company focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies focused on treating chronic and episodic diseases and conditions. The Company currently has a number of late-stage pharmaceutical products in development initially focused on significant unmet medical needs in pain management, with a number of research programs underway in a variety of other therapeutic areas. For more information, please visit http://www.durect.com .
Missing: Durect's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Durect's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Durect
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Durect is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Durect has filed 1 patent.
Food additives, Inflammations, Hepatology, Diseases of liver, Excipients
Food additives, Inflammations, Hepatology, Diseases of liver, Excipients
Latest Durect News
Nov 23, 2022
Highlights A recent analysis of clinical trial data estimates that treatment with the combination of angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers (ACE inhibitors/ARBs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors can substantially increase the lifetime survival free of kidney failure for patients with albuminuric chronic kidney disease without diabetes. A 50-year-old-patient treated with this combination may experience about 7 additional years free of kidney failure and death compared with a patient not treated with these agents. Washington, DC (November 22, 2022) — New research in CJASN highlights the potential to lower the burden of chronic kidney disease (CKD) complications by delaying or even preventing kidney failure and premature death if currently available treatments are appropriately utilized—specifically, offering patients combination therapy of angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers (ACE inhibitors/ARBs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors. About half of patients with CKD do not have diabetes but experience high rates of kidney failure and early death. These patients are typically treated with ACE inhibitors/ARBs, when presented with albuminuria (a sign of kidney disease in which a person has too much of the protein albumin in the urine). The SGLT2 inhibitor dapagliflozin, which is designed to lower blood sugar levels, has been shown to have kidney- and heart-protective effects in patients with CKD (with and without diabetes). Priya Vart, PhD (University Medical Center Groningen, in the Netherlands) and his colleagues conducted a study to estimate lifetime survival free of kidney failure for patients with albuminuric CKD without diabetes treated with the combination therapy of ACE inhibitors/ARB and SGLT2 inhibitors relative to patients not treated. The study used estimates from clinical trials of the effect of treatment with ACE inhibitors/ARBs (ramipril/benazepril) (in 690 patients) and SGLT2 inhibitors (dapagliflozin) (in 1,398 patients) compared with placebo to derive the indirect estimate of the effect of combination therapy vs. no treatment. Using this effect, investigators estimated the treatment effect of combination therapy among patients with albuminuric CKD without diabetes in the DAPA-CKD trial (697 patients) and projected kidney failure–free and overall survival for those treated and not treated with combination therapy. The primary outcome was a composite of doubling of serum creatinine (a marker of kidney dysfunction), kidney failure, or death. Combination therapy with ACE inhibitors/ARBs and SGLT2 inhibitors was associated with a 65% lower risk of the primary outcome compared with no treatment. For a 50-year-old-patient, the estimated survival free from the primary outcome was 17.0 years with the combination therapy and 9.6 years with no treatment with any of these agents, corresponding to a gain in eventfree survival of 7.4 years. Even when assuming that the effect of combination therapy is not completely additive and that treatment adherence and efficacy may wane over time, there was a gain in eventfree survival of 5.3 to 5.8 years. “The present study provides estimates of treatment benefit expressed in extra years free from the disease or death that is easy to understand for patients, clinicians, and policy makers. This may facilitate risk communication in clinical management, increase uptake of these therapies in clinical practice, and inform decision making by policy makers and payers,” the authors wrote. An accompanying editorial notes that the findings also provide a tool for advocacy efforts to improve access to and coverage for kidney-protective medicines, especially SGLT2 inhibitors, which are currently cost prohibitive to many. Additional study authors include Muthiah Vaduganathan, MD; Niels Jongs, PhD; Giuseppe Remuzzi, MD; David C. Wheeler, MD; Fan Fan Hou, PhD; Finnian McCausland, MD; Glenn M. Chertow, MD; and Hiddo J.L. Heerspink, PhD. Disclosures: G.M. Chertow reports consultancy agreements with Akebia, Ardelyx, AstraZeneca, Cricket, DiaMedica, Gilead, Miromatrix, Reata, Sanifit, Unicycive, and Vertex; ownership interest in Ardelyx, CloudCath, Durect, DxNow, Eliaz Therapeutics, Outset, Physiowave, PuraCath, and Renibus; research funding from Amgen, NIDDK, and NIAID; stock options in Ardelyx, CloudCath, Durect, and Miromatrix; was on advisory board for Reata Pharmaceuticals, Ardelyx, Baxter, CloudCath, Cricket, DiaMedica, Durect, and Miromatrix; steering committee for Akebia, AstraZeneca, Gilead, Sanifit, and Vertex; serving on the Satellite Healthcare Board of Directors and as Co-Editor of Brenner & Rector’s The Kidney (Elsevier); and DSMB service for NIDDK, Angion, Bayer, Gilead, Mineralys, Palladio, and ReCor. H.J.L. Heerspink reports ongoing consultancy agreements with AstraZeneca, Bayer, Boehringer Ingelheim, CSL Behring, Chinook, Dimerix, Eli-Lilly, Gilead, GoldFinch, Janssen, Merck, Novo Nordisk, and Travere Pharmaceuticals; research funding from AstraZeneca, Novo Nordisk and Janssen research support (grant funding directed to employer); lecture fees from AstraZeneca; speakers bureau for AstraZeneca; and funding/honoraria and consulting fees for steering committee membership and/or advisory board participation from Abbvie, AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Pharma, Dimerix, Gliead, GoldFinsch, Janssen, Fresenius, Merck, MundiPharma, Mitsubishi Tanabe, Novo Nordisk, and Travere Pharmaceuticals. F.F. Hou is a member of the DAPA-CKD study executive committee and is a study investigator. She reports personal fees from AbbVie, consultancy agreements with AstraZeneca, and honoraria from AstraZeneca. F. McCausland reports consultancy agreements with GlaxoSmithKline; research grants from National Institute of Health (NDDK), Fifth Eye, Advanced Instruments, and Satellite Healthcare; and research funding paid to institution from Advanced Medical and Fifth Eye. G. Remuzzi reports employment with Mario Negri Institute for Pharmacological Research; speaker honorarium/travel reimbursements from Alnylam, Alexion Pharmaceuticals Inc, Janssen Pharmaceutical, BioCryst Pharmaceuticals, Akebia Therapeutics, Silence Therapeutics, and Novartis - no personal remuneration is accepted, compensations are paid to his institution for research and educational activities; honoraria from Alnylam, Alexion Pharmaceuticals Inc, Janssen Pharmaceutical, Akebia Therapeutics, Catalyst Biosciences, Silence Therapeutics, and Novartis; and serving as a member of numerous editorial boards of scientific medical journals. M. Vaduganathan reports consultancy agreements with American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health; research funding from American Regent, Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim, Roche Diagnostics, Novartis, Galmed, Occlutech, and Impulse Dynamics; speakers bureau for AstraZeneca, Novartis, and Roche Diagnostics; research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Relypsa, and Roche Diagnostics; speaker engagements with Novartis and Roche Diagnostics; and participates on clinical endpoint committees for studies sponsored by Galmed and Novartis. P. Vart is an Editor for Clinical Kidney Journal. D.C. Wheeler reports consultancy agreements with Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, Napp, Mundipharma, Merck Sharp and Dohme, GlaxoSmithKline, Gilead, Tricida, Vifor Fesenius, and Zydus; honoraria from Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelhiem, Gilead, GlaxoSmithKline, Janssen, Mundipharma, Merck Sharp and Dohme, Napp, Reata, Pharmacosmos, Tricida, Vifor Fresenius, and Zidus; an advisory or leadership role for AstraZeneca; speakers bureau for Amgen, AstraZeneca, Astellas, Janssen, Mundipharma, Napp, Merck Sharp and Dohme, and Vifor Fresenius; and serving as an Honorary Professorial Fellow, George Institute for Global Health. The remaining author has nothing to disclose. The article, titled “Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes,” will appear online at http://cjasn.asnjournals.org/ on November 22, 2022, doi: 10.2215/CJN.08900722. The editorial, titled “Toward Guideline-Directed Medical Therapy in Nephrology—Lifetime Benefit of RAAS and SGLT2 Inhibition in Nondiabetic Kidney Disease,” will appear online at http://cjasn.asnjournals.org/ on November 22, 2022, doi: 10.2215/CJN.12401022. The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies. About ASN Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 20,000 members representing 132 countries. For more information, visit www.asn-online.org and follow us on Facebook , Twitter , LinkedIn , and Instagram .
Durect Web Traffic
Durect Frequently Asked Questions (FAQ)
When was Durect founded?
Durect was founded in 1998.
Where is Durect's headquarters?
Durect's headquarters is located at 2 Results Way, Cupertino.
What is Durect's latest funding round?
Durect's latest funding round is Unattributed VC - II.
How much did Durect raise?
Durect raised a total of $54.52M.
Who are the investors of Durect?
Investors of Durect include CDP Capital, Bain Capital, CHL Medical Partners, Zesiger Capital Group, Bellevue Asset Management and 15 more.
Who are Durect's competitors?
Competitors of Durect include Mirus Bio, AcelRx Pharmaceuticals, EZRA Innovations, Sagent Pharmaceuticals, Carbylan Therapeutics, Capnia, Medipacs, Catalent, Quinnova Pharmaceuticals, Orthocon and 21 more.
Compare Durect to Competitors
Core Tech Solutions, Inc. is engaged in the development of Transdermal, Dermal and Tran mucosal Delivery Systems for the treatment of a variety of indications. The primary mission of the company is to provide transdermal drug delivery development to the worlds pharmaceutical companies. In addition to offering research and development on a contractual basis, Core Tech Solutions possesses the facilities and expertise to perform or coordinate all other aspects of commercialization including Feasibility Studies, Prototype Development, Formulation Optimization, Clinical Trials, Regulatory Compliance, Process Scale-up, and Full Scale Manufacturing.
EryDel develops a red-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases. Its proprietary technology relies upon the encapsulation of drugs into red cells taken from the patient's own blood, which are then re-infused into the patient.
Pharmaceutical company focused on applying its oral drug delivery platform to develop products with improved therapeutic profiles
Glide Pharma, formerly Caretek Medical, is a specialty pharmaceutical company developing products for easy, safe and convenient delivery of pharmaceuticals and vaccines using its Glide SDI - the Solid Dose Injector. By being much less invasive than traditional injection methods, Glide improves the treatment experience of both patients and carers and, by allowing the injection of solid formulations, opens up a wide range of therapeutic options for new and existing treatments.
Kucera Pharmaceutical Company is based in Winston-Salem, NC. The company started with a drug delivery approach that combined or conjugated delivery molecules with therapeutic molecules as a platform technology, both to improve the properties of the attached therapeutic molecules (making them orally available and improving distribution) and to extend patent life.
Next Breath, LLC is a contract pharmaceutical research and development organization dedicated to pre-clinical identification and evaluation of commercially viable respiratory and nasal drug delivery platforms. NB's business will discover and exploit optimal drug and delivery device combinations that will increase the company's partners' probability of success when their products advance into human clinical trials and the marketplace. Next Breath seeks to meet the pharmaceutical industry's outsourcing needs and to provide intellectual expertise to biotechnology companies that are developing inhalation products.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.